Pregnancy and Hereditary Antithrombin Deficiency: New Study Reveals Critical Clearance Peaks at Delivery
Thrombosis Update published on its X:
“A new case study in Thrombosis Update on hereditary antithrombin deficiency (HATD) in pregnancy shows antithrombin clearance increases in the first and third trimesters, peaking around delivery.”
Title: Antithrombin supplementation to prevent venous thromboembolism: A case of hereditary antithrombin deficiency with increased antithrombin clearance during pregnancy and peripartum
Autors: Ayako Kaneda Takeuchi, Tomoaki Oda, Mei Kitamoto , Emiyu Fujiwara, Kenta Kawai, Megumi Narumi, Yoshimasa Horikoshi, Masako Matsumoto, Yukiko Kohmura-Kobayashi, Naomi Furuta-Isomura, Toshiyuki Uchida, Kazunao Suzuki, Naohiro Kanayama, Hiroaki Itoh, Naoaki Tamura.
Two-Sentence Summary (Analytical): A newly published case study highlights that antithrombin clearance significantly increases during the first and third trimesters in pregnant women with hereditary antithrombin deficiency (HATD), peaking around the time of delivery. These findings emphasize the need for dynamic monitoring of antithrombin levels throughout pregnancy to prevent thromboembolic complications in this high-risk population.
You can explore more detailed information on Hemostasis Today.
-
Nov 27, 2025, 16:00Nathan Connell on WFH AI Summaries from the Global Forum
-
Nov 27, 2025, 15:49Piotr Czempik: Rethinking Coagulation in Acute Liver Dysfunction
-
Nov 27, 2025, 15:35Overwhelmed? A Leader’s Guide from Mark Crowther to Getting Back on Track
-
Nov 27, 2025, 15:10Wolfgang Miesbach’s Top 10 Picks for TTP and Thrombosis from ASH 2025
-
Nov 27, 2025, 14:24ICCBBA’s Executive Director Eoin McGrath Chairs a Dynamic Session on AI, Innovation and Informatics in Transfusion Medicine
-
Nov 27, 2025, 13:26Wolfgang Miesbach’s Top 10 Picks for Bleeding Disorders from ASH 2025
-
Nov 27, 2025, 11:19Priya Prasad Presents a Case of Severe Hypotensive Transfusion Reaction
-
Nov 27, 2025, 04:07Eugene Tang Presents Highlights from UK Stroke Forum 2025
-
Nov 27, 2025, 03:47Michael Makris: I Believe the Time Has Come to Consider Emicizumab Up Front in Persons with Acquired Hemophilia